MOLECULIN
Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Their clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer, and AML. They are also engaged in the preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.
MOLECULIN
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2006-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.moleculin.com
Total Employee:
11+
Status:
Active
Contact:
713) 300-5160
Email Addresses:
[email protected]
Total Funding:
80.04 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-10-29 | AnnaMed | AnnaMed acquired by Moleculin | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-04 | Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer |
Official Site Inspections
http://www.moleculin.com Semrush global rank: 4.72 M Semrush visits lastest month: 2 K
- Host name: 151.101.194.159
- IP address: 151.101.194.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Moleculin"
Home - Moleculin
A late-stage pipeline of product candidates for the treatment of hard-to-treat tumors and viruses. Lead program, Annamycin, planning to commence the “MIRACLE” pivotal Phase 3 clinical trial …See details»
Moleculin Announces Corporate Rebranding and Launch of New …
HOUSTON, April 14, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates …See details»
Moleculin Biotech, Inc. | LinkedIn
Groundbreaking Cancer Therapies | Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the...See details»
Moleculin - Crunchbase Company Profile & Funding
Moleculin is a pharmaceutical company developing dermatological products to treat skin disorders. View contacts for Moleculin to access new leads and connect with decision-makers.See details»
Moleculin's Leadership Team Team - Team members and org …
Moleculin's Leadership Team includes Walter Klemp and 4 others.See details»
About - Moleculin
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses.See details»
Donald Picker - Chief Science Officer at Moleculin - The Org
Chief Science Officer at Moleculin Contact Dr. Picker has served as our chief scientific officer since August 2017 after serving as our chief operating officer from July 2015 until August 2017 …See details»
Moleculin Biotech Inc, MOL:FRA profile - FT.com - Financial Times
Mar 21, 2024 · Moleculin Biotech Inc (MOL:FRA) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Board of Directors - Moleculin
Mr. Klemp is a co-founder of our company and has served as our Chairman of the Board and Chief Executive Officer since July 2015 and as president since August 2017. Since 2006, Mr. Klemp has served as the Chairman, Co-founder and …See details»
Moleculin - Overview, News & Similar companies | ZoomInfo.com
View Moleculin (www.moleculin.com) location in Texas, United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Moleculin Biotech Company Profile - Office Locations ... - Craft
Moleculin Biotech is a pharmaceutical company focused on the development of anti-cancer drug candidates. Its lead product candidate is liposomal Annamycin, an anthracycline intended for …See details»
Moleculin Announces Corporate Rebranding and Launch of New …
Apr 14, 2022 · Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors …See details»
Moleculin Biotech, Inc. Reports Financial Results for the Year …
HOUSTON, March 24, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug …See details»
Moleculin Biotech, Inc. (MBRX) - Yahoo Finance
Find the latest Moleculin Biotech, Inc. (MBRX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial …
HOUSTON, Sept. 9, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio of drug …See details»
Moleculin Appoints Leading Expert in Pancreatic Cancer to its ...
HOUSTON, Nov. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a late stage pharmaceutical company with a broad portfolio of drug candidates …See details»
Moleculin Announces Final Topline Data from Successful European …
HOUSTON, Feb. 13, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates …See details»
Moleculin Announces Pricing of up to $16.5 Million Public Offering
Aug 16, 2024 · Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses.See details»
WPD Pharmaceuticals' STAT3 Inhibitor Received FDA Approval
Feb 20, 2020 · Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly …See details»
Moleculin to Report Third Quarter 2022 Financial Results on …
HOUSTON, Nov. 7, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates …See details»